Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PAFR inhibitor/H1 receptor inhibitor
Rupatadine is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 and 102 nM, respectively. -
PAFR inhibitor/H1 receptor inhibitor
Rupatadine is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 and 102 nM, respectively. -
thromboxane synthesis inhibitor
Ro-24-0238 is an antagonist of platelet activating factor (PAF) and inhibitor of thromboxane synthesis, used for lessening the inflammation and damage resulting from a local release of PAF. -
Platelet Aggregation Inhibitor
Epoprostenol sodium, a synthetic derivative of prostaglandin I2, primarily acts as a potent inhibitor of platelet aggregation. This compound is widely recognized for its role in the management of pulmonary arterial hypertension (PAH) and is utilized in clinical settings such as pulmonary hypertension and organ transplantation. Its ability to modulate vasodilation and inhibit platelet activation makes it a valuable tool in related biomedical research applications. -
Platelet Aggregation Inhibitor
2'-Hydroxyflavanone is a flavanone that functions as a platelet aggregation inhibitor. It demonstrates significant bioactivity by inhibiting platelet aggregation induced by arachidonic acid and adenosine diphosphate, with IC50 values of 47.8 μM and 147.2 μM, respectively. Additionally, 2'-hydroxyflavanone has been implicated in inhibiting cancer cell proliferation and inducing apoptosis, making it valuable for research in cancer and inflammatory pathways. -
Platelet Aggregation Inhibitor
Ergosta-7,22-dien-3-one functions as a platelet aggregation inhibitor, derived from the fruiting bodies of Ganoderma lucidum. This compound is known to enhance nitric oxide production and promote the expression of specific genes alongside the synthesis of Toll-like receptors (TLRs), cytokines, chemokines, and cellular adhesion molecules in vitro. Ergosta-7,22-dien-3-one is valuable for research in hematology, inflammation, and cellular signaling pathways. -
Platelet Aggregation Inhibitor
5(S),15(S)-DiHETE is a platelet aggregation inhibitor that functions as an activated intermediate in the biosynthesis of specialized pro-resolving mediators. With an IC50 of 1.3 μM, it effectively reduces platelet aggregation. Additionally, 5(S),15(S)-DiHETE enhances the rate of biosynthesis for lipoxins A4 (LXA4) and B4 (LXB4), making it valuable for research applications in inflammation and resolution processes. -
Platelet Aggregation Inhibitor
12(S)-HETrE is a fatty acid metabolite that serves as a potent inhibitor of platelet aggregation. This compound demonstrates significant biological activity in modulating thrombus formation and is valuable in thrombosis-related research applications. Researchers can utilize 12(S)-HETrE to study the molecular mechanisms underlying platelet function and explore potential therapeutic targets in cardiovascular diseases. -
Platelet Aggregation Inhibitor
Notoginsenoside Fc is a protopanaxadiol-type saponin derived from the leaves of Panax notoginseng, functioning primarily as a platelet aggregation inhibitor. This compound effectively mitigates platelet aggregation and has been shown to enhance reendothelialization after vascular injury in diabetic rat models by promoting autophagy. Its biological activity makes Notoginsenoside Fc a valuable reagent for research in cardiovascular health and vascular regeneration. -
Platelet Aggregation Inhibitor
SCH 38519 is a potent platelet aggregation inhibitor that effectively inhibits thrombin-induced aggregation of human platelets, exhibiting an IC50 of 68 μg/mL. In addition to its antiplatelet activity, SCH 38519 demonstrates antibacterial properties against both Gram-positive and Gram-negative bacteria. This compound is valuable for research applications focused on thrombosis, cardiovascular diseases, and bacterial infections. -
Platelet Aggregation Inhibitor
D-RGDW is a synthetic peptide containing the Arg-Gly-Asp (RGD) sequence, which targets the αIIbβ3 integrin. It effectively inhibits platelet aggregation, making it a valuable tool for research into thrombosis and hemostasis. D-RGDW can be utilized in various biochemical studies focused on vascular biology and the mechanisms of platelet activation. -
Glycoprotein IIb-IIIa/Platelet Aggregation Inhibitor
Variabilin is a potent antagonist of glycoprotein IIb-IIIa, functioning primarily as a platelet aggregation inhibitor. Isolated from the hard tick Dermacentor variabilis, Variabilin effectively inhibits platelet aggregation induced by various agonists, including ADP, collagen, and thrombin receptor peptide SFLLRNP. Additionally, it hinders platelet adhesion to immobilized fibrinogen (Fg) and blocks the binding of purified human GPIIb-IIIa to immobilized Fg. This compound is valuable for research applications in hematology and thrombosis. -
Platelet Aggregation Inhibitor
U-51605 is a platelet aggregation inhibitor that targets thromboxane synthesis. It also functions as a prostaglandin I2 synthase inhibitor and has been shown to block retinal vasodilation responses induced by nitric oxide donors like NOR3. This reagent is valuable for research applications focusing on cardiovascular health and vascular biology. -
platelet aggregation inhibitor
Trifenagrel is an orally active platelet aggregation inhibitor that targets the pathways induced by arachidonic acid and collagen. It demonstrates significant biological activity, with ED50 values of 1.4 mg/kg and 9.4 mg/kg for the inhibition of AA- and collagen-induced platelet aggregation in guinea pigs, respectively. This compound serves as a valuable tool in cardiovascular research and the study of thrombotic disorders. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
TSI-01 is a selective inhibitor of the Platelet-activating Factor Receptor (PAFR), targeting lysophosphatidylcholine acyltransferase (LPCAT)2. This compound exhibits a potent inhibitory effect with an IC50 of 0.47 μM for human LPCAT2, significantly more effective than its activity on LPCAT1 (IC50 = 3.02 μM). TSI-01 effectively suppresses PAF biosynthesis in mouse peritoneal macrophages when stimulated with a calcium ionophore at a concentration of 60 μM. This makes TSI-01 a valuable tool for investigating inflammatory processes and related conditions in research applications. -
Platelet Aggregation Inhibitor
2-Acetylbenzoic acid is a derivative of benzoic acid that functions as a weak inhibitor of platelet aggregation. It specifically inhibits adenosine 5'-diphosphate (ADP)-induced platelet aggregation, making it valuable for research in cardiovascular biology and thrombotic disorders. This compound can be utilized to study the role of platelet activation in various disease models and therapeutic interventions. -
PAFR Inhibitor
Cryptomeridiol is an inhibitor of the platelet-activating factor (PAF) receptor. It demonstrates significant melanogenesis inhibitory activity in α-MSH-stimulated B16 melanoma cells, making it a valuable tool for research into pigmentation processes and potential therapeutic applications in melanoma. Its mechanisms may contribute to a better understanding of PAF signaling in various biological contexts. -
Platelet Aggregation Inhibitor
Preschisanartanin O is a potent platelet aggregation inhibitor derived from Schisandra lancifolia. It effectively inhibits platelet aggregation induced by platelet-activating factor (PAF), highlighting its potential role in cardiovascular research. This compound is valuable for studies investigating thrombus formation and related pathological conditions, providing insight into therapeutic strategies for managing platelet-related disorders. -
Platelet Aggregation-related Pathway Inhibitor
MKC-963 is a potent, orally active inhibitor targeting platelet aggregation-related pathways. This compound exhibits significant antithrombotic activity by disrupting platelet aggregation mechanisms. Additionally, MKC-963 induces autoinduction of CYP3A4, leading to enhanced metabolism in vivo. It is a valuable tool for research into platelet aggregation-related diseases, such as thrombosis. -
Platelet Aggregation Inhibitor
(R,R)-MK 287 is a potent platelet aggregation inhibitor targeting platelet-activating factor (PAF) pathways. It demonstrates strong inhibition of PAF binding to human platelets, polymorphonuclear leukocytes, and lung membranes, with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 effectively prevents PAF-induced platelet aggregation and elastase release from PMNs, with ED50 values of 56 nM and 4.4 nM, respectively. Additionally, it reduces PAF-induced lethality in murine models and bronchospasm in guinea pigs, showcasing its potential applications in inflammatory and cardiovascular research. -
Arachidonic Acid Metabolism/Platelet Aggregation Inhibitor
Rhazimine is an indole alkaloid that serves as a dual inhibitor of arachidonic acid metabolism and platelet aggregation induced by platelet activating factor. This compound demonstrates significant biological activity by modulating inflammatory pathways and inhibiting platelet aggregation, making it valuable for research in cardiovascular diseases and related pharmacological studies. Rhazimine's mechanism may provide insights into the development of therapeutic strategies targeting vascular inflammation and thrombotic conditions. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
Dersalazine is a selective inhibitor of the platelet-activating factor receptor (PAFR), demonstrating significant intestinal anti-inflammatory properties. This compound shows potential efficacy in the treatment of ulcerative colitis, making it a valuable tool for research into inflammatory bowel diseases. Its ability to modulate PAFR-mediated signaling pathways makes Dersalazine a pertinent candidate for exploring therapeutic strategies targeting inflammation and related gastrointestinal disorders. -
PAF Inhibitor
CV 3988 is a selective inhibitor of platelet-activating factor (PAF), a lipid mediator involved in various inflammatory processes. By blocking PAF activity, CV 3988 demonstrates potential in mitigating inflammation-related pathways and may be valuable in studying conditions influenced by PAF. This compound is suitable for research applications in inflammation, cardiovascular diseases, and related areas of biochemical investigation. -
PAFR Inhibitor
Piperulin A is a selective inhibitor of the platelet-activating factor receptor (PAFR). It effectively disrupts the specific binding of PAFR on isolated rabbit platelet plasma membranes, demonstrating an IC50 value of 7.3 μM. This compound is valuable for research applications focused on understanding PAFR-related signaling pathways and their implications in various physiological and pathological processes. -
PAF Inhibitor
Pinusolidic acid is an inhibitor of platelet-activating factor (PAF), demonstrating an IC50 value of 23 μM. This compound is primarily utilized in research to study the roles of PAF in various biological processes and diseases, including inflammation and thrombosis. Its inhibitory properties make it a valuable tool for investigating PAF-related pathways and potential therapeutic applications. -
Platelet Aggregation Inhibitor
Aggreceride A is a potent platelet aggregation inhibitor that targets multiple pathways involved in thrombosis. It exhibits significant inhibitory activity against platelet aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet-activating factor (PAF), making it valuable for cardiovascular research. However, it demonstrates reduced efficacy against collagen-induced aggregation. This compound is suitable for studying mechanisms of platelet function and the effects of aggregation inhibitors in various therapeutic contexts. -
PAF Inhibitor
BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist. It inhibits PAF signaling, which plays a crucial role in various physiological processes, including inflammation and thrombosis. BN 52111 is primarily utilized in research applications to investigate the role of PAF in disease models and to explore potential therapeutic interventions. -
Platelet Aggregation Inhibitor
Aggreceride B is a potent platelet aggregation inhibitor targeting pathways involved in thrombus formation. It effectively inhibits platelet aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet activating factor (PAF), while demonstrating reduced activity against collagen-induced aggregation. This compound is valuable in studies focused on thromboembolic diseases and platelet function analysis. -
Platelet Aggregation Inhibitor
Aggreceride C is a potent platelet aggregation inhibitor targeting multiple pathways involved in platelet activation. It effectively inhibits aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet activating factor (PAF) while demonstrating reduced activity against collagen-induced aggregation. This compound is valuable for research applications focused on thrombosis and vascular biology. -
Platelet Aggregation Inhibitor
17-Phenyl-18,19,20-trinor-PGD2 is a potent inhibitor of platelet aggregation that primarily targets adenosine diphosphate (ADP) signaling pathways. It demonstrates an IC50 of 8.4 μM, significantly outperforming prostaglandin D2 (PGD2), which has an IC50 of 18.6 nM. Additionally, 17-Phenyl-18,19,20-trinor-PGD2 serves as a weak agonist for cyclic AMP accumulation, making it a valuable tool for research in cardiovascular and hemostatic studies. -
Platelet Aggregation Inhibitor
Octimibate is a non-prostaglandin platelet aggregation inhibitor, acting primarily to prevent platelet activation and aggregation. This compound is utilized in research focused on cardiovascular diseases, specifically in the contexts of atherosclerosis and thrombosis, to elucidate the underlying mechanisms and potential therapeutic strategies for these conditions. -
Platelet Aggregation Inhibitor
MED 27 is a potent inhibitor of thromboxane synthase and thromboxane A2 receptors. It effectively inhibits rat platelet aggregation at significantly lower doses compared to acetylsalicylic acid. This compound is valuable for research applications focused on cardiovascular disorders and the mechanisms of platelet function. -
Platelet Aggregation Inhibitor
CRL42872 free base is a potent oral platelet aggregation inhibitor that targets the mechanisms involved in platelet activation and aggregation. It effectively modulates platelet function, making it valuable for studying various cardiovascular and thrombotic disorders. Researchers can utilize CRL42872 free base to explore its potential therapeutic applications and elucidate the role of platelet aggregation in disease mechanisms. -
Platelet Aggregation Inhibitor
Myrianthic acid is a pentacyclic triterpenoid that functions as a platelet aggregation inhibitor. Isolated from the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora, it effectively inhibits adrenaline-induced platelet aggregation, demonstrating an IC50 of 46.2 μM. This compound is valuable for research applications focused on thrombosis and related cardiovascular disorders. -
Blood Platelet Aggregation Inhibitor
Ent-8-Iso-15(S)-prostaglandin F2α is a potent inhibitor of blood platelet aggregation. This compound exhibits superior activity compared to its isomer, 8-Isoprostaglandin F2α, in whole blood assays, making it a valuable tool for studying platelet function and related cardiovascular research. Its mechanism of action can aid in the exploration of therapeutic strategies for conditions associated with abnormal platelet aggregation. -
PAFAH1b2/1b3 Inhibitor
P11 is a selective inhibitor of platelet-activating factor acetylhydrolases (PAFAHs) 1b2 and 1b3, demonstrating significant impairment of cancer cell survival. With IC50 values of approximately 40 nM for PAFAH1b2 and 900 nM for PAFAH1b3, P11 is a valuable tool for investigating the role of these enzymes in cancer biology and related research applications, including studies focused on cell proliferation and apoptosis. -
Platelet Aggregation Inhibitor
Cloricromen is a potent platelet aggregation inhibitor that functions by targeting the mechanisms involved in thrombus formation. Demonstrating efficacy in inhibiting platelet aggregation in both human subjects and experimental models, Cloricromen is a valuable reagent for research in cardiovascular disease and thrombotic disorders. Its application in studying platelet function and related pathologies makes it an essential tool for investigations in vascular biology. -
Platelet Aggregation Inhibitor
4-Trifluoromethylsalicylic acid, also known as Desacetyl triflusal, functions as a platelet aggregation inhibitor. This compound is instrumental in research related to cardiovascular disorders, particularly in the study of thrombus formation and prevention. Its ability to modulate platelet activity makes it a valuable tool for investigating hematological processes and developing antithrombotic therapies. -
Platelet Aggregation Inhibitor
Ataprost is a potent platelet aggregation inhibitor that functions as an orally active analogue of Carboprostacyclin. This compound demonstrates 2.6 times greater efficacy than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Additionally, Ataprost has been shown to alleviate coronary spasm, making it relevant for research in cardiovascular diseases and platelet function studies. -
Platelet Aggregation Inhibitor
Evategrel is a potent platelet aggregation inhibitor that primarily targets ADP receptors on platelets. This compound effectively reduces thrombus formation, making it useful for research in cardiovascular diseases and the study of clotting mechanisms. Its ability to modulate platelet activity supports investigations into antiplatelet therapies and their applications in preventing thrombotic events. -
Platelet Aggregation Inhibitor
Prostaglandin I3 sodium is a potent inhibitor of platelet aggregation, primarily acting through the stimulation of adenylate cyclase, which increases cyclic AMP levels in platelets. This compound also exhibits vasodilatory properties, making it useful in studies related to cardiovascular health and thrombotic disorders. Its applications include research into the modulation of vascular tone and the prevention of platelet-related complications in various disease models. -
Platelet Aggregation Inhibitor
Cloricromen hydrochloride is a potent platelet aggregation inhibitor that effectively targets and modulates platelet activation pathways. This compound has demonstrated the ability to inhibit platelet aggregation in both human and experimental thrombosis models, making it a valuable reagent for research into cardiovascular diseases and thrombotic disorders. Cloricromen hydrochloride is suitable for studies focused on the mechanisms of platelet function and the development of antithrombotic therapies. -
Platelet Aggregation Inhibitor
KP-10614 is a potent, orally active inhibitor of platelet aggregation, primarily targeting ADP-induced aggregation with an IC50 of 1 nM. This compound exhibits dose-dependent inhibition of ex vivo platelet aggregation in rat models. KP-10614 demonstrates significant antithrombotic effects across various thrombosis models, making it a valuable tool for research into thrombotic diseases.
